Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Reducing the risk of failure: biomarker-guided trial design

Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

    Article  CAS  Google Scholar 

  2. Chan, A. C. & Behrens, T. W. Personalizing medicine for autoimmune and inflammatory diseases. Nat. Immunol. 14, 106–109 (2013).

    Article  CAS  Google Scholar 

  3. Arron, J. R., Townsend, M. J., Keir, M. E., Yaspan, B. L. & Chan, A. C. Stratified medicine in inflammatory disorders: from theory to practice. Clin. Immunol. 161, 11–22 (2015).

    Article  CAS  Google Scholar 

  4. Smith, K. G. & Clatworthy, M. R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328–343 (2010).

    Article  CAS  Google Scholar 

  5. Tzouvelekis, A., Herazo-Maya, J., Sakamoto, K. & Bouros, D. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Curr. Top. Med. Chem. 16, 1587–1598 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph R. Arron.

Ethics declarations

Competing interests

M.J.T. and J.R.A. are employees of Genentech Inc. and hold stock and options in the Roche Group.

Supplementary information

Supplementary information S1 (figure)

Supplementary figure legend (PDF 308 kb)

Related links

Related links

FURTHER INFORMATION

Clinical Development Success Rates: 2006–2015

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Townsend, M., Arron, J. Reducing the risk of failure: biomarker-guided trial design. Nat Rev Drug Discov 15, 517–518 (2016). https://doi.org/10.1038/nrd.2016.124

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.124

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research